Pediatric Study Required To Monitor Repel-CV Cardiac Adhesion Barrier
This article was originally published in The Gray Sheet
Executive Summary
Life Medical Sciences is modifying its pivotal study protocol for the Repel-CV bioresorbable adhesion barrier film to reflect a more appropriate follow-up period by concentrating on neonatal patients suffering from left hyperplastic heart syndrome